{'fraction_non_alphanumeric': 0.02045209903121636, 'fraction_numerical': 0.0, 'mean_word_length': 5.739130434782608, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
PLASMA O‐METHYLDOPA IN LEVODOPA‐INDUCED DYSKINESIAS A Bioclinical Investigation

The peripheral metabolism of Dopa has been studied in correlation with the clinical occurrence of Levodopa‐induced dyskinesias in Parkinson patients. Within the group of patients treated with a peripheral decarboxylase inhibitor (PDI), the combination of all the plasma levels of O‐Methyldopa from patients with dyskinesias shows significantly higher values than those from patients without dyskinesias. For Dopa itself, no significant difference can be detected. Such high O‐Methyldopa levels seem to be due to a progressive accumulation of this compound and not to a higher degree of formation. In contrast, no significantly different Dopa or O‐Methyldopa levels are found within the group of patients treated with L‐Dopa alone. These results are discussed in relation to some of the suspected mechanisms involved in Levodopa‐induced dyskinesias.